Navigation Links
Genomic Health Announces Appointment of Ginger Graham to Board of Directors
Date:12/8/2008

ents, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. To date, 7,500 physicians have ordered more than 75,000 tests, and both Medicare and private health plans covering approximately 90 percent of U.S. insured lives provide reimbursement for Oncotype DX through contracts, agreements and policy decisions. Both the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network recommend the use of Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. For more information about Oncotype DX, please visit http://www.oncotypedx.com.

About Genomic Health

Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test, Oncotype DX(R), which has been shown to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit in a large portion of early-stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit http://www.genomichealth.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's mission to make individualized treatment standard practice for cancer patients, the ability of the company
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Rosetta Genomics to Webcast Panel Presentation at RBC Capital Markets 2008 Healthcare Conference
2. Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium
3. Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS
4. Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products Neurodegenerative Diagnostics
5. Rosetta Genomics Announces Conference Call and Webcast of Third Quarter Financial Results
6. Transgenomic Awarded SBIR Grant to Support Development of SURVEYOR(R) Endonuclease Adaptor-ligated Libraries (SEAL) for Determining Whole Genome Sequence Variation
7. Genomic Health to Present at Stephens Fall Investment Conference
8. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
9. NeoGenomics to Present at the Rodman & Renshaw Healthcare Conference on November 10
10. Transgenomic to Present at Rodman & Renshaw 10th Annual Healthcare Conference
11. /C O R R E C T I O N -- Rosetta Genomics Ltd/
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Protocol Networks brings independent ... team of brand-neutral, independent consultants, Protocol Networks has recently ... that over the years, his company has attracted several ... of Plainfield, as well as others. With the success ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Dr. Greg Leyer ... 12th annual Scripps Natural Supplements Pre-Conference seminar on probiotics in ... is an annual continuing education conference for health care professionals. ... included the topic of probiotics in health. Dr. Leyer spoke ...
(Date:1/22/2015)... Nueva Jersey , 22 de enero de 2015  El ... abre hoy su llamada a nominaciones para 2015. Este ... ha hecho, o tiene el potencial para hacer, contribuciones ... nominaciones se aceptarán hasta el 15 de marzo de ...
(Date:1/22/2015)... 22, 2015  Derma Sciences, Inc. (Nasdaq: ... advanced wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, ... added to the Premier, Inc. Regenerative Skin Grafting ... the AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue ...
Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
... This release from ... -- or even whether -- invasive saltcedar should be controlled. The Society contends that ... and carefully weigh the impact of our decisions. , ... Lawrence, KS (PRWEB) August 24, 2009 -- Saltcedar (Tamarix spp.) is ...
... LEIDEN, The Netherlands and SEATTLE, August ... innovative products for hemostasis and,regenerative medicine, today announced the ... The financing round was led by new investor,Gilde Healthcare ... investor Index Ventures. Dirk Kersten from Gilde will join ...
... , SEATTLE, Aug. 21 Cell ... closing of its previously announced sale of $30 million of shares ... of its common stock in a registered offering to a single ... its shares of Series 2 Preferred Stock and to receive the ...
Cached Biology Technology:Invasive Saltcedar Triggers Lively Debate among Weed Scientists and Land Managers 2Invasive Saltcedar Triggers Lively Debate among Weed Scientists and Land Managers 3ProFibrix Raises US $11 Million (EUR 8 million) in Series B Financing 2ProFibrix Raises US $11 Million (EUR 8 million) in Series B Financing 3Cell Therapeutics, Inc. Announces Closing of Registered Offering of $30 Million of Preferred Stock and Warrants 2
(Date:1/22/2015)... Jan. 22, 2015   EyeLock, Inc. , a market leader ... Steve Gerber to the new role of Senior ... for leading development of mobile platforms and wearable solutions for ... and innovation in the semiconductor industry to his role at ...
(Date:12/24/2014)... , Dec. 23, 2014  Since its launch in December 2014, the ... eliminate the pain of trying to remember their usernames and ... fused to their smartphones. To assist people who have struggled ... company that created 1U and focuses on redefining identity, announced ...
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... of the "The Global Watermarking and Fingerprinting ... http://photos.prnewswire.com/prnh/20130307/600769 This ... media watermarking and fingerprinting markets. Watermarking aims to ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3The Global Watermarking and Fingerprinting Markets 2
... BioScience includes the following peer-reviewed articles: Molecular ... Patrick J. Tranel and David P. Horvath. , Modern ... development of herbicide-resistant crops and a better understanding of ... of tools, including genomics, could yield novel and still ...
... system response that is critical to the first stages ... an entirely different direction than most scientists had thought, ... University Medical Center. "This finding will have ... development," said Michael Gunn, M.D., an immunologist and cardiologist ...
... Christopher Fasano (Memorial Sloan-Kettering Cancer Center) and colleagues lend ... stem cells outside of the neurogenic niche. , ... Bmi-1, maintains forebrain neural stem cell self-renewal. Overexpression of ... increases stem cell self-renewal both in vitro and in ...
Cached Biology News:BioScience tip sheet, March 2009 2New origin found for a critical immune response 2
... One can operate as a Voltage Clamp, as ... Clamp in electrophysiology research applications. Performance in any ... equipment. • This amazing ... in the capabilities of Digital Signal Processing (DSP) ...
... an enhanced ChemStation for the ... 2000 and Windows XP operating ... all new 7500 ICP-MS instruments ... new ChemStation using Microsofts Windows ...
... Microarrays designed for genome-wide microRNA expression ... and powerful Paraflo microfluidic on-chip synthesis ... part of our comprehensive microRNA Expression ... The Soil Nematode microRNA Microarray ...
... to the maintenance of appropriate levels ... important and diverse as those involved ... stress response, antigen presentation, modulation of ... cell cycle regulation, transcription, and signalling ...
Biology Products: